ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Investigating the predictive role of inflammatory indices in cancer metastasis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly detection of metastasis in cancer patients plays a pivotal role in improving treatment outcomes and increasing patient survival. This study aimed to evaluate the predictive role of inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune inflammation index (SII), and systemic inflammation response index (SIRI), in identifying metastatic status.
methodsIn this study, 60 cancer patients were enrolled between December 2023 and June 2024. Clinicopathological data and complete blood counts (CBCs) were collected prior to treatment initiation. The Receiver Operating Characteristic (ROC) curve was used to determine the optimal cutoff values of different baseline inflammatory indices for the metastatic status analysis.
resultsThe levels of inflammatory indices were greater in metastatic patients than in nonmetastatic patients; however, only the SIRI was significantly different (1.04 [0.76-1.69] vs. 0.71 [0.45-1.07]; P = 0.044). ROC curve analysis revealed that the area under the curve (AUC) for the SIRI was 0.652 (95% CI 0.507-0.797). Furthermore, broader combinations of the SIRI and MLR, either individually or in conjunction with the NLR, PLR, and/or SII, yielded multi-index models with greater discriminatory power and maintained statistical significance (p < 0.05).
conclusionThe findings indicate that the SIRI, in combination with the MLR, plays a significant role in predicting the metastatic status of cancer patients.
Indexed as
Identifiers
41196459What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.